An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: Significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms

American Journal of Surgical Pathology

Volumn 29, Issue 8, 2005, Pages 1034-1041

  O'Neill, Ciaran J ^a   Deavers, Michael T ^b   Malpica, Anais ^b   Foster, Heather ^a   McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

High grade; Immunohistochemistry; Low grade; Ovary; Serous carcinoma

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; OSTEOPONTIN; PROTEIN BCL 2; PROTEIN P53; STEM CELL FACTOR; SURVIVIN; WT1 PROTEIN;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; CYSTADENOMA; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR GENETICS; OVARY CARCINOMA; PATHOGENESIS; PROTEIN EXPRESSION;

CYSTADENOMA, SEROUS; FEMALE; HUMANS; KI-67 ANTIGEN; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OSTEOPONTIN; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, ERBB-2; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; WT1 PROTEINS;

EID: 22944486725     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mutinous carcinomas of the peritoneum, fallopian tube, ovary and endometrium. Int J Gynecol Pathol. 2004;23: 110-118.
2. Al-Hussaini M, Stockman A, Foster H, et al. WT1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44: 109-115.
3. Chan WY, Cheung K-K, Schorge JO, et al. Bcl-2 and p53 protein expression, apoptosis and p53 mutation in human epithelial ovarian cancers. Am J Pathol. 2000;156:409-417.
4. Cohen C, Lohmann CM, Cotsonis G, et al. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognsosis. Mod Pathol. 2003;16:574-583.
5. Diebold J, Amann G, Seemuller F, et al. Diagnostic and molecular genetic pathology of serous borderline tumours of the ovary. Curr Diagn Pathol. 2004;10:318-325.
6. Eichhorn JH, Bell DA, Young RH, et al. Ovarian serous borderline tumors wth micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without the pattern. Am J Surg Pathol. 1999;23: 397-409.
7. Feeley KM, Well M. Precursor lesions of ovarian epithelial malignancy. Histopathology. 2001;32:87-95.
8. Fields AC, Cotsonis G, Sexton D, et al. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters and outcome. Mod Pathol. 2004;17:1378-1385.
9. Frutuoso C, Silva MR, Amaral N, et al. Prognostic value of p53, C-erb-2 and Ki67 proteins in ovarian carcinoma. Acta Med Port. 2001;14:277-283.
10. Gershenson DM. Is micropapillary serous carcinoma for real? Cancer. 2002;95:677-680.
11. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002;117:541-545.
12. Hashi A, Yuminamochi T, Murata SI, et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium and peritoneum. Int J Gynecol Pathol. 2004;22: 374-377.
13. Ho C-L, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64:6915-6918.
14. Hockenberry D, Nunez G, Millinan C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334-336.
15. Hwang H, Quenneville L, Yaziji H, et al. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol. 2004;12: 122-126.
16. Ji H, Singer G, Kurman RJ, et al. Tumor cell proliferation activity coordinates with clinical aggressiveness of ovarian serous carcinomas. Mod Pathol. 2003;16:194A.
17. Johnson ME, Howerth EW Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol 2004;41:599-607.
18. Katabuchi H, Tashiro H, Cho KR, et al. Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53. Int J Gynecol Pathol. 1998;17:54-60.
19. Kempson RL, Hendrickson MR. Ovarian serous borderline tumors: the Citadel defended. Hum Pathol 2000;31:525-526.
20. Khalifeh I, Banyopadhyay S, Malone JM, et al. Low expression of c-kit associated with high expression of Ki-67 and poor prognosis in advanced ovarian serous carcinoma. Mod Pathol. 2004;17:199A.
21. Kostopoulou E, Kaisaridou D, Ioannou M, et al. C-erbB2 status in ovarian carcinomas: a combined evaluation using FISH, CISH and immunohistochemistry. Mod Pathol. 2005;18:190A.
22. Levine AJ, Moment J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453-456.
23. Lewis F, Jackson P, Lane S, et al. Testing for HER2 in breast cancer. Histopathology. 2004;45:207-217.
24. Liapis H, Adler LM, Wick MR, et al. Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol. 1997;28:443-449.
25. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol. 2003;27:1434-1441.
26. Ma XY, He FX, Wu SF, et al. Expression of survivin in ovarian epithelial carcinoma and its correlation with expression of Fas and FasL. Ai Zheng. 2004;23:173-176.
27. Maki M, Hirota S, Kaneko Y, et al. Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. Pathol Int. 2000;50:531-535.
28. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496-504.
29. Malpica A, Deavers MT, Tornos C, et al. Interobserver variability of the two-tier system for grading ovarian serous carcinoma. Mod Pathol. 2005; 18:194A.
30. Malyz J, Lee SW, Nazir TM, et al. Survivin expression in epithelial ovarian neoplasia. Mod Pathol. 2005;18:901A.
31. McCluggage WG, WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol. 2004;23:97-99.
32. McCluggage WG, Oliva E, Connolly LE, et al. An immunohistocehmical analysis of ovarian small cell carcinoma of hypercalcaemic type. Int J Gynecol Pathol. 2004;23:330-336.
33. McManus DT, Yap EP, Maxwell P, et al. p53 expression, mutation and allelic deletion in ovarian cancer. J Pathol. 1994;174:159-168.
34. Mosquera JM, Meehan K, Rotmensch J, et al. COX-2, EGFR, WT-1 and HER-2/neu expression in epithelial ovarian tumours. Mod Pathol. 2005; 18:909A.
35. Munakata S, Enomoto T, Tsujimoto M, et al. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer. 2000;82:1446-1452.
36. Prat J. Serous tumors of the ovary (borderline tumors and carcinomas) with and without micropapillary features. Int J Gynecol Pathol. 2002;22: 25-28.
37. Prat J, De Nictolis M. Serous borderline rumours of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26:1111-1128.
38. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature. 1990;346; 194-197.
39. Raspollini MR, Amunni G, Villanucci A, et al. C-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. Ann Oncol. 2004;15:594-597.
40. Riener EK, Arnold N, Kommoss F, et al. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecol Oncol. 2004;95:89-94.
41. Russell HE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol. 2004;203:617-619.
42. Schmandt RE, Broaddus R, Lu KH, et al. Expression of c-ABL, C-KIT and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003;98: 758-764.
43. Seidman JD, Ronnett BM, Kurman RJ. Evolution of the concept and terminology of borderline ovarian tumours. Curr Diagn Pathol. 2000;6: 31-37.
44. Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164: 1511-1518.
45. Shimuzu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilm's tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158-163.
46. Sieben NLG, Macropoulos P, Roemen GMJM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutation are restricted to low-grade serous tumours. J Pathol. 2004;202:336-340.
47. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223-1228.
48. Singer G, Shih IM, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma. Int J Gynecol Pathol 2003;22:37-41.
49. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005; 29:218-224.
50. Smith Sehdev AE, Sehdev PS, Kurman RJ, Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol. 2003;27:725-736.
51. Staebler A, Heselmeyer-Haddad K, Bell K, et al. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridisation compared with atypical serous tumors and serous carcinomas. Hum Pathol. 2002;33:47-59.
52. Sui L, Dong Y, Ohno M, et al. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumours. Int J Oncol. 2002;21:315-320.
53. Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential. Hum Pathol. 1998;29: 1250-1254.
54. Tonary AM, Macdonald EA, Faught W, et al. Lack of expression of C-KIT in ovarian cancers is associated with a poor prognosis. Int J Cancer. 2000; 89:242-250.
55. Tucker Burks R, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996;20:1319-1330.
56. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001;1552:61-85.
57. Wu Y, Soslow R, Marshall DS, et al. HER-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol. 2004;95:570-575.
58. Yeatman TJ, Chambers AF. Osteopontin and colon cancer progression. Clin Exp Metas. 2003;20:85-90.